WINNIPEG, MANITOBA--(Marketwire - 07/25/11) - Medicure Inc. (the “Company”) (TSX-V:MPH.H - News) is pleased to announce that Mr. Dawson Reimer has been appointed President and Chief Operating Officer of the Company effective July 25, 2011. In this capacity, Mr. Reimer will be responsible for the Company’s commercial direction, day-to-day operations, and strategic development, including the advancement and management of new and existing pharmaceutical products.
Dr. Albert D. Friesen continues to serve as the Chief Executive Officer of the Company and as Chair of its Board of Directors under the amended and renewed agreement with the Company announced on July 18, 2011.
Dawson Reimer has worked with Medicure since 1997 and has served in the capacity of Vice President, Operations since June 2004. Over the past 14 years he has overseen most aspects of the Company’s business including product development and all facets of the Company’s commercial operations surrounding the sales and marketing of AGGRASTAT®. Most recently, Mr. Reimer managed the Company’s restructuring process leading up to the debt settlement announced on July 18, 2011 and negotiated the collaborative agreement with Iroko Cardio, LLC announced July 6, 2011. In addition to his services to the Company, Mr. Reimer has consulted to a variety of public and private life science ventures and currently serves as Chair of the Life Science Association of Manitoba. Mr. Reimer holds a Masters Degree in Economic Development from the University of Waterloo.
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel small molecules to treat cardiovascular and neurological disorders. The primary business activity of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT® (tirofiban HCl) for acute coronary syndromes in the United States, where it is sold through the Company’s US subsidiary, Medicure Pharma, Inc.
Forward Looking Information
Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words “believes”, “may”, “plans”, “will”, “estimates”, “continues”, “anticipates”, “intends”, “expects” and similar expressions, may constitute “forward-looking information” within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements are based on the current assumptions, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company’s ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements.
Such risk factors include, among others, the Company’s future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company’s products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company’s revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company’s research and development projects; the availability of financing for the Company’s commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company’s other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the “Risk Factors” section of its Form 20F for the year ended May 31, 2010.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Contacts:Medicure Inc.Albert D. Friesen, Ph.D.Chief Executive Officer888-435-2220204-488-9823 (FAX)info@medicure.comwww.medicure.com
